Connection

Donald Castell to Gastric Acid

This is a "connection" page, showing publications Donald Castell has written about Gastric Acid.
Connection Strength

6.284
  1. Sporadic Fundic Gland Polyps and Gastric Acid Suppression Level. Am J Med Sci. 2017 12; 354(6):561-564.
    View in: PubMed
    Score: 0.561
  2. Concomitant Administration of a Histamine2 Receptor Antagonist and Proton Pump Inhibitor Enhances Gastric Acid Suppression. Pharmacotherapy. 2015 Dec; 35(12):1124-9.
    View in: PubMed
    Score: 0.500
  3. Comparison of reflux frequency during prolonged multichannel intraluminal impedance and pH monitoring on and off acid suppression therapy. J Clin Gastroenterol. 2009 Oct; 43(9):816-20.
    View in: PubMed
    Score: 0.326
  4. Symptoms with acid and nonacid reflux may be produced by different mechanisms. Dis Esophagus. 2009; 22(5):467-70.
    View in: PubMed
    Score: 0.312
  5. Twenty-four hour ambulatory simultaneous impedance and pH monitoring: a multicenter report of normal values from 60 healthy volunteers. Am J Gastroenterol. 2004 Jun; 99(6):1037-43.
    View in: PubMed
    Score: 0.225
  6. Nocturnal acid breakthrough: pH, drugs and bugs. Eur J Gastroenterol Hepatol. 2004 May; 16(5):441-3.
    View in: PubMed
    Score: 0.224
  7. Nocturnal acid breakthrough in perspective: let's not throw out the baby with the bath water. Am J Gastroenterol. 2003 Mar; 98(3):517-8.
    View in: PubMed
    Score: 0.207
  8. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology. 2001 Jun; 120(7):1599-606.
    View in: PubMed
    Score: 0.183
  9. Maximal acid reflux control for Barrett's oesophagus: feasible and effective. Aliment Pharmacol Ther. 2001 Apr; 15(4):519-24.
    View in: PubMed
    Score: 0.181
  10. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther. 2000 Oct; 14(10):1267-72.
    View in: PubMed
    Score: 0.175
  11. Prior sensitization of esophageal mucosa by acid reflux predisposes to reflux-induced chest pain. J Clin Gastroenterol. 2000 Sep; 31(2):121-4.
    View in: PubMed
    Score: 0.174
  12. Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole. Aliment Pharmacol Ther. 2000 Jun; 14(6):709-14.
    View in: PubMed
    Score: 0.171
  13. Acid suppression therapy in Barrett's esophagus: the importance of pH monitoring. Curr Gastroenterol Rep. 2000 Jun; 2(3):173-4.
    View in: PubMed
    Score: 0.171
  14. Importance of adequate acid suppression in the management of Barrett's esophagus. Gastroenterology. 1999 Dec; 117(6):1509-10.
    View in: PubMed
    Score: 0.165
  15. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology. 1998 Dec; 115(6):1335-9.
    View in: PubMed
    Score: 0.154
  16. Acid secretion from an esophageal inlet patch demonstrated by ambulatory pH monitoring. Gastroenterology. 1998 Dec; 115(6):1574-6.
    View in: PubMed
    Score: 0.154
  17. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther. 1998 Dec; 12(12):1231-4.
    View in: PubMed
    Score: 0.154
  18. Normal patterns of acid exposure at the gastric cardia: a functional midpoint between the esophagus and stomach. Am J Gastroenterol. 1998 Aug; 93(8):1236-42.
    View in: PubMed
    Score: 0.150
  19. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol. 1998 May; 93(5):763-7.
    View in: PubMed
    Score: 0.148
  20. Acid control and regression of Barrett's esophagus: is the glass half full or half empty? Am J Gastroenterol. 1997 Dec; 92(12):2329-30.
    View in: PubMed
    Score: 0.144
  21. Effective gastric acid suppression after oral administration of enteric-coated omeprazole granules. Dig Dis Sci. 1997 Apr; 42(4):715-9.
    View in: PubMed
    Score: 0.137
  22. Sensitization of esophageal mucosa by prior acid infusion: effect of decreasing intervals between infusions. Am J Gastroenterol. 1996 Sep; 91(9):1745-8.
    View in: PubMed
    Score: 0.132
  23. Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy. Am J Gastroenterol. 1996 Aug; 91(8):1527-31.
    View in: PubMed
    Score: 0.131
  24. Optimal dosing of omeprazole 40 mg daily: effects on gastric and esophageal pH and serum gastrin in healthy controls. Am J Gastroenterol. 1996 Aug; 91(8):1532-8.
    View in: PubMed
    Score: 0.131
  25. Changes in overnight fasting intragastric pH show poor correlation with duodenogastric bile reflux in normal subjects. Am J Gastroenterol. 1996 Aug; 91(8):1567-70.
    View in: PubMed
    Score: 0.131
  26. Omeprazole, serum gastrin, and gastric acid suppression. Ann Intern Med. 1995 Feb 01; 122(3):237-8.
    View in: PubMed
    Score: 0.118
  27. Histamine H2 receptor stimulation increases gastric emptying in monkeys. Am J Physiol. 1988 Dec; 255(6 Pt 1):G767-71.
    View in: PubMed
    Score: 0.077
  28. Addition of a H2 receptor antagonist to PPI improves acid control and decreases nocturnal acid breakthrough. J Clin Gastroenterol. 2008 Jul; 42(6):676-9.
    View in: PubMed
    Score: 0.075
  29. Review article: acidity and volume of the refluxate in the genesis of gastro-oesophageal reflux disease symptoms. Aliment Pharmacol Ther. 2007 May 01; 25(9):1003-17.
    View in: PubMed
    Score: 0.069
  30. Review article: complete gastro-oesophageal reflux monitoring - combined pH and impedance. Aliment Pharmacol Ther. 2006 Sep; 24 Suppl 2:27-37.
    View in: PubMed
    Score: 0.066
  31. Intragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: an open-label crossover study in healthy adult volunteers. Clin Ther. 2006 May; 28(5):725-33.
    View in: PubMed
    Score: 0.064
  32. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut. 2006 Oct; 55(10):1398-402.
    View in: PubMed
    Score: 0.064
  33. Review of immediate-release omeprazole for the treatment of gastric acid-related disorders. Expert Opin Pharmacother. 2005 Nov; 6(14):2501-10.
    View in: PubMed
    Score: 0.062
  34. Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study. Aliment Pharmacol Ther. 2004 Aug 15; 20(4):399-406.
    View in: PubMed
    Score: 0.057
  35. The acidity index: a simple approach to the measurement of gastric acidity. Aliment Pharmacol Ther. 2004 Feb 15; 19(4):443-8.
    View in: PubMed
    Score: 0.055
  36. Use of multichannel intraluminal impedance to document proximal esophageal and pharyngeal nonacidic reflux episodes. Am J Med. 2003 Aug 18; 115 Suppl 3A:119S-123S.
    View in: PubMed
    Score: 0.053
  37. Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther. 2003 Jan; 17(2):243-51.
    View in: PubMed
    Score: 0.051
  38. Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers. Aliment Pharmacol Ther. 2002 Apr; 16(4):829-36.
    View in: PubMed
    Score: 0.048
  39. Over-the-counter H(2)-receptor antagonists do not compromise intragastric pH control with proton pump inhibitors. Aliment Pharmacol Ther. 2002 Mar; 16(3):473-7.
    View in: PubMed
    Score: 0.048
  40. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther. 2001 Sep; 15(9):1351-6.
    View in: PubMed
    Score: 0.047
  41. Experimental study of acid burden and acute oesophagitis. Br J Surg. 1998 May; 85(5):677-80.
    View in: PubMed
    Score: 0.037
  42. Control of gastric acid with high dose H2-receptor antagonists after omeprazole failure: report of two cases. Am J Gastroenterol. 1995 Oct; 90(10):1874-7.
    View in: PubMed
    Score: 0.031
  43. Omeprazole failure in a patient with gastroesophageal reflux disease. Ann Intern Med. 1994 Dec 01; 121(11):899.
    View in: PubMed
    Score: 0.029
  44. Rationale for high-dose H2-receptor blockade in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1991; 5 Suppl 1:59-67.
    View in: PubMed
    Score: 0.022
  45. The changing paradigm of GERD. Curr Gastroenterol Rep. 2007 Dec; 9(6):441-2.
    View in: PubMed
    Score: 0.018
  46. Medical therapy for reflux esophagitis: 1986 and beyond. Ann Intern Med. 1986 Jan; 104(1):112-4.
    View in: PubMed
    Score: 0.016
  47. Future medical therapy of reflux esophagitis. J Clin Gastroenterol. 1986; 8 Suppl 1:81-5.
    View in: PubMed
    Score: 0.016
  48. Drugs, foods, and other substances in the cause and treatment of reflux esophagitis. Med Clin North Am. 1981 Nov; 65(6):1223-34.
    View in: PubMed
    Score: 0.012
  49. The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2000 Nov; 14(11):1503-9.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.